奥拉帕尼联合阿比特龙与安慰剂联合阿比特龙在治疗无症状/轻度症状和有症状的转移性去势抵抗性前列腺癌一线治疗中的疗效与安全性：来自第3期PROpel试验的分析
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
正在获取期刊数据...
发表日期:2025 Apr
作者:
DOI:10.1016/j.euo.2024.09.013
摘要
AI正在翻译并加载中文摘要...